MELANOMA RESEARCH
Scope & Guideline
Transforming Knowledge into Melanoma Solutions.
Introduction
Aims and Scopes
- Clinical Research and Trials:
The journal publishes studies from clinical trials, providing insights into the efficacy and safety of various melanoma therapies, including immunotherapies, targeted therapies, and combination treatments. - Molecular and Genetic Studies:
Research focusing on the molecular and genetic underpinnings of melanoma, including studies on mutations (e.g., BRAF, NRAS), gene expression profiles, and the role of epigenetics in melanoma pathogenesis. - Immunology and Immune Responses:
Investigations into the immune landscape of melanoma, including the role of immune checkpoint inhibitors, immune-related adverse events, and the interactions between melanoma cells and the immune system. - Epidemiology and Public Health:
Studies addressing the epidemiology of melanoma, including incidence, mortality rates, and the impact of social factors such as the COVID-19 pandemic on diagnosis and treatment. - Diagnostic and Prognostic Biomarkers:
Research focused on identifying biomarkers that can predict treatment response, disease progression, and patient outcomes, enhancing personalized medicine approaches in melanoma care. - Innovative Treatment Strategies:
Exploration of novel therapeutic approaches, including the use of artificial intelligence in diagnosis, new drug combinations, and emerging treatment modalities.
Trending and Emerging
- Immunotherapy and Immune Checkpoint Inhibitors:
There is a notable increase in research focused on immune checkpoint inhibitors, their mechanisms of action, and the management of immune-related adverse events, showcasing the growing importance of immunotherapy in melanoma treatment. - Real-World Evidence and Outcomes:
Recent studies emphasize real-world data and outcomes in melanoma treatment, providing insights into how therapies perform outside of clinical trial settings, which is crucial for understanding their effectiveness in diverse patient populations. - Artificial Intelligence and Machine Learning Applications:
The integration of artificial intelligence and machine learning in melanoma diagnosis and management is gaining traction, with studies exploring their potential to enhance diagnostic accuracy and personalize treatment strategies. - Molecular Profiling and Personalized Medicine:
A trend towards personalized medicine is evident, with increasing research on molecular profiling to tailor therapies based on individual patient tumor characteristics, enhancing treatment efficacy. - Impact of COVID-19 on Melanoma Care:
The pandemic's effect on melanoma diagnosis, treatment delays, and outcomes has emerged as a significant area of research, reflecting the need to understand and mitigate the impact of global health crises on cancer care.
Declining or Waning
- Traditional Chemotherapy Approaches:
Research on conventional chemotherapy agents for melanoma has decreased, reflecting a broader shift towards targeted therapies and immunotherapy, which are now considered the standard of care. - Single-Agent Therapy Studies:
There has been a reduction in studies focusing solely on single-agent therapies, as the trend moves towards combination therapies that leverage multiple mechanisms of action to improve patient outcomes. - Descriptive Studies without Novel Insights:
The frequency of purely descriptive studies regarding melanoma characteristics without significant novel insights or implications for treatment has diminished, as the journal increasingly prioritizes research with direct clinical relevance.
Similar Journals
Case Reports in Oncology
Connecting the Global Oncology CommunityCase Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.
Hematology
Transforming Hematology: Open Access to Tomorrow's DiscoveriesHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
Trends in Cancer
Advancing Cancer Research with Insightful InnovationsTrends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.
PATHOLOGY & ONCOLOGY RESEARCH
Pioneering Discoveries in Pathology and OncologyPATHOLOGY & ONCOLOGY RESEARCH is a prominent international journal published by FRONTIERS MEDIA SA, dedicated to advancing the fields of pathology and oncology. Operating from the Netherlands, with a distinguished address in Switzerland, this journal plays a crucial role in disseminating significant research findings and insights from 1995 to 2024. With an ISSN of 1219-4956 and E-ISSN of 1532-2807, it is indexed in well-respected databases, facilitating access to a global audience of researchers and practitioners. Notably, the journal ranks in the Q3 category for Cancer Research (2023), while being recognized in the Q2 categories for both Medicine (Miscellaneous), Oncology, and Pathology and Forensic Medicine, reflecting its authoritative status in these vital disciplines. Scopus rankings further highlight its influence, with notable percentiles across various fields. Although it follows a subscription model, the journal remains committed to publishing high-quality, peer-reviewed research that bridges conceptual gaps and encourages further exploration in oncology and diagnostic pathology, making it an indispensable resource for academics and professionals engaged in these critical areas of medicine.
Kidney Cancer
Innovating insights for better patient care in kidney cancer.Kidney Cancer, published by IOS PRESS, is an esteemed open-access journal dedicated to advancing knowledge in the field of nephrology and oncology. Since its inception in 2017, this journal has provided a dynamic platform for researchers, practitioners, and students to disseminate their findings and discuss innovative approaches to kidney cancer treatment and research. With an ongoing commitment to fostering collaboration and sharing critical insights, Kidney Cancer aims to bridge gaps in understanding and promote new methodologies in patient care. Despite its current ranking in the lower quartiles of its category, the journal is positioned to make significant contributions to the academic community by publishing high-quality, peer-reviewed articles that enhance the discourse in kidney cancer research. Furthermore, its open-access model ensures that valuable research is accessible to a global audience, supporting the urgent need for advancements in this critical area of health. Join the conversation and contribute to the growing body of knowledge in this vital field.
Pigment Cell & Melanoma Research
Connecting Researchers in the Fight Against Melanoma.Pigment Cell & Melanoma Research is a premier journal published by Wiley that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, genetics, molecular biology, dermatology, and oncology. With its ISSN of 1755-1471 and E-ISSN 1755-148X, the journal is recognized for its impactful contributions to advancing our understanding of pigment cells and melanoma, particularly from 2008 to 2024. The journal currently holds a commendable Q1 ranking across major categories, including dermatology and oncology, and demonstrates an impressive 96th percentile ranking in the field of medicine’s dermatology category. While the journal is not open access, it offers researchers valuable insights into the latest findings and innovations in skin biology and cancer research. By publishing rigorous peer-reviewed articles, Pigment Cell & Melanoma Research aims to foster collaboration and education within the scientific community, making it an indispensable tool for anyone dedicated to the study of pigmentation disorders and melanoma.
npj Breast Cancer
Advancing the frontiers of breast cancer research.npj Breast Cancer, published by NATURE PORTFOLIO, stands at the forefront of breast cancer research as an esteemed open access journal since 2015. With its impressive trajectory, the journal has garnered a notable impact within the academic community, reflecting a Q1 ranking in prestigious categories such as Oncology, Pharmacology, and Radiology for 2023. Based in the United Kingdom and indexed under E-ISSN 2374-4677, npj Breast Cancer aims to disseminate cutting-edge research that fosters innovation in prevention, diagnosis, and treatment of breast cancer, thereby addressing one of the most pressing health issues of our time. Its placement within Scopus rankings, including a remarkable 19th position in Pharmacology and a percentile ranking in the 90th range for Radiology and Oncology, highlights its significance as a key resource for researchers, healthcare professionals, and policy-makers dedicated to advancing cancer care. Emphasizing accessibility and high-quality content, npj Breast Cancer provides an influential platform for interdisciplinary collaboration and discovery in the ongoing battle against breast cancer.
Journal of Hematology & Oncology
Fostering Excellence in Hematology and Oncology ScholarshipJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
World Journal of Clinical Oncology
Fostering Collaboration in the Fight Against CancerWorld Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.
Journal of Hepatocellular Carcinoma
Advancing knowledge in liver cancer research.The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.